Review article: the emerging interplay among the gastrointestinal tract, bile acids and incretins in the pathogenesis of diabetes and non‐alcoholic fatty liver disease

Recent research has led to an interest in the role of the gut and liver in type 2 diabetes mellitus (T2DM).

[1]  S. Klein,et al.  Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease , 2012, Hepatology.

[2]  P. Tontonoz,et al.  Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR , 2012, Nature Reviews Molecular Cell Biology.

[3]  R. Loomba,et al.  Meta‐analysis: pioglitazone improves liver histology and fibrosis in patients with non‐alcoholic steatohepatitis , 2012, Alimentary pharmacology & therapeutics.

[4]  A. Belfiore,et al.  The Role of Metformin in the Management of NAFLD , 2011, Experimental diabetes research.

[5]  S. Turner,et al.  Effect of bile acid sequestrants on glucose metabolism, hepatic de novo lipogenesis, and cholesterol and bile acid kinetics in type 2 diabetes: a randomised controlled study , 2012, Diabetologia.

[6]  I. Kamel,et al.  Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study , 2011, BMJ : British Medical Journal.

[7]  A. Hofmann,et al.  Bile acid sequestrants improve glycemic control in type 2 diabetes: A proposed mechanism implicating glucagon‐like peptide 1 release , 2011, Hepatology.

[8]  Irl B Hirsch,et al.  American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[9]  M. Stockton,et al.  Acute Pancreatitis Associated with Liraglutide , 2011, The Annals of pharmacotherapy.

[10]  K. Sung,et al.  Interrelationship between fatty liver and insulin resistance in the development of type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[11]  M. Taskinen,et al.  Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study , 2011, Diabetes, obesity & metabolism.

[12]  V. Ventura,et al.  Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study , 2010, International Journal of Obesity.

[13]  G. Musso,et al.  A meta‐analysis of randomized trials for the treatment of nonalcoholic fatty liver disease , 2010, Hepatology.

[14]  F. Knop.  Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes? , 2010, American journal of physiology. Endocrinology and metabolism.

[15]  J. Holst,et al.  Glucose-Dependent Insulinotropic Polypeptide May Enhance Fatty Acid Re-esterification in Subcutaneous Abdominal Adipose Tissue in Lean Humans , 2010, Diabetes.

[16]  Jennifer M. Trujillo,et al.  Association of Pancreatitis with Glucagon-Like Peptide-1 Agonist Use , 2010, The Annals of pharmacotherapy.

[17]  F. van der Leij,et al.  Regulatory enzymes of mitochondrial β‐oxidation as targets for treatment of the metabolic syndrome , 2010, Obesity reviews : an official journal of the International Association for the Study of Obesity.

[18]  A. Lusis,et al.  Early Hepatic Insulin Resistance Precedes the Onset of Diabetes in Obese C57BLKS-db/db Mice , 2010, Diabetes.

[19]  J. Holst,et al.  Colesevelam improves insulin resistance in a diet-induced obesity (F-DIO) rat model by increasing the release of GLP-1. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[20]  V. Fonseca,et al.  Bile Acid Sequestrants for Lipid and Glucose Control , 2010, Current diabetes reports.

[21]  B. Zinman,et al.  Changes in Prandial Glucagon Levels after 2-year Treatment with Vildagliptin or Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy Short title: Glucagon after vildagliptin versus glimepiride , 2010 .

[22]  U. Akarca,et al.  Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease , 2010, European journal of gastroenterology & hepatology.

[23]  W. Wright.  The management of type 2 diabetes mellitus: a novel approach for addressing glycemic and lipid control with colesevelam HCl. , 2009, Advance for nurse practitioners.

[24]  H. Itoh,et al.  Serum bile acid along with plasma incretins and serum high-molecular weight adiponectin levels are increased after bariatric surgery. , 2009, Metabolism: clinical and experimental.

[25]  J. Auwerx,et al.  TGR5-mediated bile acid sensing controls glucose homeostasis. , 2009, Cell metabolism.

[26]  J. Holst,et al.  Serum Bile Acids Are Higher in Humans With Prior Gastric Bypass: Potential Contribution to Improved Glucose and Lipid Metabolism , 2009, Obesity.

[27]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[28]  R. DeFronzo,et al.  The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone , 2009, Diabetes Care.

[29]  J. Egan,et al.  Exogenous Glucose–Dependent Insulinotropic Polypeptide Worsens Post prandial Hyperglycemia in T ype 2 Diabetes , 2009, Diabetes.

[30]  K. Birkeland,et al.  Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial , 2009, Scandinavian journal of gastroenterology.

[31]  J. Hoofnagle,et al.  Clinical trial: pilot study of metformin for the treatment of non‐alcoholic steatohepatitis , 2009, Alimentary pharmacology & therapeutics.

[32]  O. Tawfik,et al.  Farnesoid X Receptor Deficiency Induces Nonalcoholic Steatohepatitis in Low-Density Lipoprotein Receptor-Knockout Mice Fed a High-Fat Diet , 2009, Journal of Pharmacology and Experimental Therapeutics.

[33]  Jason K. Kim,et al.  Fibroblast Growth Factor 21 Reverses Hepatic Steatosis, Increases Energy Expenditure, and Improves Insulin Sensitivity in Diet-Induced Obese Mice , 2009, Diabetes.

[34]  B. Staels,et al.  Role of bile acids and bile acid receptors in metabolic regulation. , 2009, Physiological reviews.

[35]  O. Gedik,et al.  The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease , 2009, Acta Diabetologica.

[36]  R. Goldberg,et al.  Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. , 2008, Archives of internal medicine.

[37]  C. Deacon,et al.  Incretin and islet hormonal responses to fat and protein ingestion in healthy men. , 2008, American journal of physiology. Endocrinology and metabolism.

[38]  J. Rosenstock,et al.  Colesevelam HCl Improves Glycemic Control and Reduces LDL Cholesterol in Patients With Inadequately Controlled Type 2 Diabetes on Sulfonylurea-Based Therapy , 2008, Diabetes Care.

[39]  R. Goldberg,et al.  Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. , 2008, Archives of internal medicine.

[40]  Andrea Mari,et al.  Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients , 2008, Diabetes.

[41]  Mark Ellrichmann,et al.  Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance , 2008, Diabetes.

[42]  J. Girard,et al.  Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. , 2008, Diabetes & metabolism.

[43]  V. Alves,et al.  Combination of N‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitis , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[44]  C. Knauf,et al.  Glucagon-like peptide-1 and energy homeostasis. , 2007, The Journal of nutrition.

[45]  Sten Madsbad,et al.  Reduced Incretin Effect in Type 2 Diabetes , 2007, Diabetes.

[46]  P. J. Larsen,et al.  Characterization of brainstem preproglucagon projections to the paraventricular and dorsomedial hypothalamic nuclei , 2007, Brain Research.

[47]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[48]  G. Ronnett,et al.  Modulation of carnitine palmitoyltransferase-1 for the treatment of obesity. , 2007, Current opinion in investigational drugs.

[49]  S. Dejager,et al.  Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes. , 2007, Diabetes research and clinical practice.

[50]  Yoosoo Chang,et al.  Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. , 2007, Clinical chemistry.

[51]  M. Nauck,et al.  Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial , 2007, Diabetes, obesity & metabolism.

[52]  T. Ogihara,et al.  Prevention and Treatment of Obesity, Insulin Resistance, and Diabetes by Bile Acid–Binding Resin , 2007, Diabetes.

[53]  J. Holst,et al.  Reduced Incretin Effect in Type 2 Diabetes - Cause or Consequence of the Diabetic State? Received for publication 23 January 2007 and accepted in revised form 3 May 2007. , 2007 .

[54]  J. Hardies,et al.  A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. , 2006, The New England journal of medicine.

[55]  Dennis D. Kim,et al.  Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin , 2006, Diabetes/metabolism research and reviews.

[56]  J. Holst,et al.  Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. , 2006, The Journal of clinical endocrinology and metabolism.

[57]  B. Wicksteed,et al.  Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level , 2006, Diabetologia.

[58]  Folkert Kuipers,et al.  The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice* , 2006, Journal of Biological Chemistry.

[59]  Ke Ma,et al.  Farnesoid X receptor is essential for normal glucose homeostasis. , 2006, The Journal of clinical investigation.

[60]  J. Egan,et al.  Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP. , 2006, American journal of physiology. Endocrinology and metabolism.

[61]  G. Farrell,et al.  Nonalcoholic fatty liver disease: From steatosis to cirrhosis , 2006, Hepatology.

[62]  J. Auwerx,et al.  Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation , 2006, Nature.

[63]  Timothy M Willson,et al.  Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[64]  R. Batterham,et al.  Gut Hormone Profiles Following Bariatric Surgery Favor an Anorectic State, Facilitate Weight Loss, and Improve Metabolic Parameters , 2006, Annals of surgery.

[65]  M. Nauck,et al.  Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes , 2006, Diabetologia.

[66]  R. DePinho,et al.  The Kinase LKB1 Mediates Glucose Homeostasis in Liver and Therapeutic Effects of Metformin , 2005, Science.

[67]  C. Mcintosh,et al.  Glucose-dependent Insulinotropic Polypeptide (GIP) Stimulation of Pancreatic β-Cell Survival Is Dependent upon Phosphatidylinositol 3-Kinase (PI3K)/Protein Kinase B (PKB) Signaling, Inactivation of the Forkhead Transcription Factor Foxo1, and Down-regulation of bax Expression* , 2005, Journal of Biological Chemistry.

[68]  Stephen R. Bloom,et al.  The inhibitory effects of peripheral administration of peptide YY3–36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal–brainstem–hypothalamic pathway , 2005, Brain Research.

[69]  G. Marchesini,et al.  A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease , 2005, The American Journal of Gastroenterology.

[70]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[71]  G. Tsujimoto,et al.  Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. , 2005, Biochemical and biophysical research communications.

[72]  K. Petersen,et al.  Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.

[73]  P. Angulo,et al.  Nonalcoholic fatty liver disease. , 2002, Revista de gastroenterologia de Mexico.

[74]  H. Stam,et al.  Lipid metabolism of myocardial endothelial cells , 1992, Molecular and Cellular Biochemistry.

[75]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. , 2004, Diabetes care.

[76]  Henry Buchwald,et al.  Bariatric surgery: a systematic review and meta-analysis. , 2004, JAMA.

[77]  J. Holst,et al.  Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. , 2004, American journal of physiology. Endocrinology and metabolism.

[78]  J. Horton,et al.  Molecular mediators of hepatic steatosis and liver injury. , 2004, The Journal of clinical investigation.

[79]  R. Soriano,et al.  Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. , 2004, Endocrinology.

[80]  E. Kraegen,et al.  Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. , 2004, Biochemical and biophysical research communications.

[81]  T. Kigoshi,et al.  Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells , 2004, Autonomic Neuroscience.

[82]  W. Creutzfeldt,et al.  Insulin-dependent inhibition of hepatic glycogenolysis by gastric inhibitory polypeptide (GIP) in perfused rat liver , 1986, Diabetologia.

[83]  J. Polak,et al.  Electronimmunocytochemical evidence for the K cell localization of gastric inhibitory polypeptide (GIP) im man , 1978, Histochemistry.

[84]  G. Wittert,et al.  Hormonal Changes after Roux-en Y Gastric Bypass for Morbid Obesity and the Control of Type-II Diabetes Mellitus , 2004, The American surgeon.

[85]  L. Kuller,et al.  Effect of Laparoscopic Roux-En Y Gastric Bypass on Type 2 Diabetes Mellitus , 2003, Annals of surgery.

[86]  H. Noushmehr,et al.  Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. , 2003, Endocrinology.

[87]  D. D’Alessio,et al.  Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect. , 2003, American journal of physiology. Endocrinology and metabolism.

[88]  J. Holst,et al.  Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects , 2003, Regulatory Peptides.

[89]  S. Kliewer,et al.  Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. , 2003, Genes & development.

[90]  J. Holst,et al.  Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. , 2003, The Journal of clinical endocrinology and metabolism.

[91]  J. Holst,et al.  Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. , 2003, The Journal of clinical endocrinology and metabolism.

[92]  J. Holst,et al.  Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia , 2003, Diabetologia.

[93]  D. Moller,et al.  Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[94]  R. Pederson,et al.  Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis. , 2003, American journal of physiology. Endocrinology and metabolism.

[95]  Masataka Harada,et al.  A G Protein-coupled Receptor Responsive to Bile Acids* , 2003, The Journal of Biological Chemistry.

[96]  P. Flatt,et al.  Cooperative enhancement of insulinotropic action of GLP-1 by acetylcholine uncovers paradoxical inhibitory effect of beta cell muscarinic receptor activation on adenylate cyclase activity. , 2003, Biochemical pharmacology.

[97]  M. Prentki,et al.  Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor. , 2003, Diabetes.

[98]  M. Prentki,et al.  Glucagon-Like Peptide 1 Induces Pancreatic β-Cell Proliferation Via Transactivation of the Epidermal Growth Factor Receptor , 2003 .

[99]  Takao Nakamura,et al.  Identification of membrane-type receptor for bile acids (M-BAR). , 2002, Biochemical and biophysical research communications.

[100]  I. Valverde,et al.  Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. , 2002, The Journal of endocrinology.

[101]  A. Anisfeld,et al.  BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. , 2002, Journal of lipid research.

[102]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[103]  D. Hörsch,et al.  Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. , 2001, Molecular endocrinology.

[104]  J. Holst,et al.  Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. , 2001, The Journal of clinical endocrinology and metabolism.

[105]  J. Holst,et al.  Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. , 2001, Diabetes.

[106]  K. Wada,et al.  Reduced GLP-1 and insulin responses and glucose intolerance after gastric glucose in GRP receptor-deleted mice. , 2000, American journal of physiology. Endocrinology and metabolism.

[107]  E. Mannucci,et al.  Glucagon‐like peptide (GLP)‐1 and leptin concentrations in obese patients with Type 2 diabetes mellitus , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[108]  Xia Li,et al.  Portal GLP-1 administration in rats augments the insulin response to glucose via neuronal mechanisms. , 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

[109]  L. Moore,et al.  A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.

[110]  D. Marguet,et al.  Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[111]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[112]  G. Marchesini,et al.  Association of nonalcoholic fatty liver disease with insulin resistance. , 1999, The American journal of medicine.

[113]  J. Holst,et al.  Glucagon-Like Peptide-1-(7-36)Amide Is Transformed to Glucagon-Like Peptide-1-(9-36)Amide by Dipeptidyl Peptidase IV in the Capillaries Supplying the L Cells of the Porcine Intestine1. , 1999, Endocrinology.

[114]  J. Lehmann,et al.  Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.

[115]  C. Beglinger,et al.  rapid communication Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2 , 2022 .

[116]  P. Brubaker,et al.  Printed in U.S.A. Copyright © 1999 by The Endocrine Society Role of the Vagus Nerve in Mediating Proximal Nutrient- Induced Glucagon-Like Peptide-1 Secretion* , 2022 .

[117]  J. Holst,et al.  Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. , 1999, Endocrinology.

[118]  P. Flatt,et al.  Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle. , 1998, The Journal of endocrinology.

[119]  A. Astrup,et al.  Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. , 1998, The Journal of clinical investigation.

[120]  J. Holst,et al.  Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. , 1997, American journal of physiology. Endocrinology and metabolism.

[121]  J. Holst,et al.  Reduced gastric inhibitory polypeptide but normal glucagon-like peptide 1 response to oral glucose in postmenopausal women with impaired glucose tolerance. , 1997, European journal of endocrinology.

[122]  J. Holst,et al.  Rapid oscillations in plasma glucagon-like peptide-1 (GLP-1) in humans: cholinergic control of GLP-1 secretion via muscarinic receptors. , 1997, The Journal of clinical endocrinology and metabolism.

[123]  J. Holst,et al.  Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. , 1996, The American journal of physiology.

[124]  J. Holst,et al.  Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. , 1996, The Journal of clinical endocrinology and metabolism.

[125]  B. Göke,et al.  Regulation of glucagon-like peptide-1 secretion from rat ileum by neurotransmitters and peptides. , 1995, The Journal of endocrinology.

[126]  W. Pories,et al.  Who Would Have Thought It? An Operation Proves to Be the Most Effective Therapy for Adult‐Onset Diabetes Mellitus , 1995, Annals of surgery.

[127]  S. Mojsov,et al.  Tissue‐specific expression of the human receptor for glucagon‐like peptide‐I: brain, heart and pancreatic forms have the same deduced amino acid sequences , 1995, FEBS letters.

[128]  B. Göke,et al.  Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. , 1995, Digestion.

[129]  J. Egan,et al.  Glucagon-like peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. , 1994, Endocrinology.

[130]  M. Brownstein,et al.  Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. , 1993, Endocrinology.

[131]  P. Brubaker,et al.  Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. , 1993, Endocrinology.

[132]  V. Marks,et al.  Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. , 1993, The Journal of endocrinology.

[133]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[134]  M. Nauck,et al.  Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7-36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. , 1993, The Journal of clinical endocrinology and metabolism.

[135]  J. Habener,et al.  Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) , 1993, Nature.

[136]  J. Holst,et al.  Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. , 1993, The Journal of clinical investigation.

[137]  H. Vermeer,et al.  Glucagon‐like peptide‐1 cells in the gastrointestinal tract and pancreas of rat, pig and man , 1992, European journal of clinical investigation.

[138]  G. Dohm,et al.  Surgical treatment of obesity and its effect on diabetes: 10-y follow-up. , 1992, The American journal of clinical nutrition.

[139]  M. Classen,et al.  GLP-1-(7-36) amide, -(1-37), and -(1-36) amide: potent cAMP-dependent stimuli of rat parietal cell function. , 1991, The American journal of physiology.

[140]  P. Brubaker,et al.  Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. , 1991, Endocrinology.

[141]  J. Holst,et al.  Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. , 1991, The Journal of clinical investigation.

[142]  M. Hegen,et al.  The T cell triggering molecule Tp103 is associated with dipeptidyl aminopeptidase IV activity. , 1990, Journal of immunology.

[143]  M. Nauck,et al.  Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8. , 1989, The Journal of clinical endocrinology and metabolism.

[144]  K. Meyer zum Büschenfelde,et al.  Tissue distribution of the T cell activation antigen Ta1. Serological, immunohistochemical and biochemical investigations. , 1988, Clinical and experimental immunology.

[145]  J. Sjövall,et al.  Altered bile acid profiles in duodenal bile and urine in diabetic subjects , 1988, European journal of clinical investigation.

[146]  S. Bloom,et al.  GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN , 1987, The Lancet.

[147]  K. Shima,et al.  Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. , 1987, Endocrinology.

[148]  D. Drucker,et al.  Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[149]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[150]  E. Reinherz,et al.  Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody. , 1984, Journal of immunology.

[151]  G. Bell,et al.  Hamster preproglucagon contains the sequence of glucagon and two related peptides , 1983, Nature.

[152]  Graeme I. Bell,et al.  Exon duplication and divergence in the human preproglucagon gene , 1983, Nature.

[153]  M. Gregor,et al.  Gut hormones in tropical malabsorption. , 1979, British medical journal.

[154]  E. Mazzaferri,et al.  The insulinotropic effect of endogenous gastric inhibitory polypeptide in normal subjects. , 1976, The Journal of clinical endocrinology and metabolism.

[155]  J. Brown,et al.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man. , 1973, The Journal of clinical endocrinology and metabolism.

[156]  J. Brown,et al.  Inhibition of histamine-, pentagastrin-, and insulin-stimulated canine gastric secretion by pure "gastric inhibitory polypeptide". , 1972, Gastroenterology.

[157]  H. Elrick,et al.  PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. , 1964, The Journal of clinical endocrinology and metabolism.

[158]  N. Mcintyre,et al.  NEW INTERPRETATION OF ORAL GLUCOSE TOLERANCE. , 1964, Lancet.

[159]  W. H. Hattie.  Mechanism of Pancreatic Secretion. , 1926, Canadian Medical Association journal.

[160]  M. Bernard.  DEFECT OF ORGANIZATION IN THE EXTERNAL EAR. , 1824 .